TELA Bio (TELA) Piper Sandler 36th Annual Healthcare Conference summary

Market dynamics and industry trends

• IV shortages and hurricane disruptions have not significantly impacted recent performance, but inventory workdowns and supply chain adjustments may affect results later in the quarter, especially in general surgery and hernia repair, which are sensitive to such factors.

• A major polypropylene mesh settlement is expected to drive a significant market transition over the next few years, with 80% of hernia implants potentially shifting away from permanent plastics, creating opportunities for alternative products.

• The transition from permanent to temporary plastic meshes is underway, with only a few companies positioned to benefit; product compatibility with robotic surgery and cost-effectiveness are key differentiators.

• The timeline for market change is expected to mirror the OB-GYN mesh precedent, with momentum building from next year and accelerating through 2026–2027.

• International growth, especially in the UK and Europe, is strong, with shared decision-making models and patient preference driving adoption.

Operational and financial outlook

• Q4 is projected to see a $4 million sequential revenue increase, driven by seasonal factors, patient scheduling, and increased sales rep and physician activity.

• Growth is attributed to deeper penetration within existing hospital systems and broadening product usage, particularly in robotic and minimally invasive procedures.

• PRS is expected to outpace hernia in growth due to its smaller base and expanding international presence.

• OpEx reductions of $5–$10 million are anticipated in 2025, mainly from restructuring the sales force and reducing support roles, enabling flat OpEx with continued top-line growth.

• Operating income profitability is targeted at or below $30–$35 million in quarterly revenue, with recent capital raises providing additional financial cushion.

Strategic initiatives and product development

• Efforts are underway to reclassify products to avoid contract caps and improve hospital economics, with education as a key strategy.

• New product launches, such as IHR for inguinal hernia and LIQUIFIX fixation device, are broadening the portfolio and positioning the company as a comprehensive hernia repair provider.

• PRS business is supported by emerging clinical data and ongoing studies, with regulatory progress and IDE labeling initiatives expected to be catalysts over the next two to three years.

• GPO contract coverage is nearly complete, with one major contract up for bid next year; renewal by HealthTrust signals strong performance.

• Growth for 2025 is expected to exceed 25%, driven by both existing and new territories, with additional levers available for further acceleration.